Wings for Life

Axonis Therapeutics is a biotechnology company focused on developing therapies for neurological disorders by targeting the KCC2, a key mediator of inhibition in the brain. The company leverages groundbreaking research from institutions such as Boston Children’s Hospital, Harvard, and Laval University to create a proprietary neuron-specific K-Cl cotransporter discovery engine. This innovative platform aims to enhance the treatment of various conditions, including epilepsy, pain, and other central nervous system pathologies, by fine-tuning neuronal inhibition. Through its efforts, Axonis Therapeutics seeks to contribute to the healthcare industry's ability to combat neurodegeneration, restore neuronal excitation, and promote neuron regeneration, ultimately improving the quality of life for individuals affected by these disorders.

ReNetX Bio, Inc. is a biotechnology company focused on developing and marketing therapeutics aimed at treating injuries and damage to the central nervous system (CNS). The company provides Nogo Trap, a decoy receptor that binds growth inhibitors to facilitate natural nerve fiber growth, promoting axonal regeneration, sprouting, and synaptic plasticity. ReNetX Bio's therapeutic offerings address conditions such as spinal cord injury, stroke, and glaucoma. The company, originally founded as Axerion Therapeutics in 2009, rebranded to ReNetX Bio in July 2017 and is headquartered in New Haven, Connecticut. Its innovative approach includes the development of small molecule oral compounds designed to block harmful protein interactions in the brain, thereby supporting recovery in patients with various CNS disorders.